Concepts (226)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cost-Benefit Analysis | 26 | 2022 | 142 | 4.980 |
Why?
|
| Breast Neoplasms | 19 | 2023 | 1426 | 4.820 |
Why?
|
| Patient Readmission | 6 | 2023 | 74 | 4.430 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 8 | 2020 | 178 | 3.330 |
Why?
|
| Decision Making | 9 | 2021 | 189 | 2.780 |
Why?
|
| Receptor, erbB-2 | 10 | 2020 | 122 | 2.330 |
Why?
|
| Decision Support Techniques | 7 | 2020 | 48 | 1.830 |
Why?
|
| Models, Economic | 7 | 2021 | 18 | 1.630 |
Why?
|
| Myocardial Ischemia | 2 | 2023 | 72 | 1.630 |
Why?
|
| Drug Costs | 5 | 2020 | 28 | 1.470 |
Why?
|
| Retrospective Studies | 15 | 2023 | 1961 | 1.430 |
Why?
|
| Humans | 58 | 2023 | 34853 | 1.430 |
Why?
|
| Disease-Free Survival | 5 | 2017 | 114 | 1.390 |
Why?
|
| Hospital Mortality | 2 | 2020 | 183 | 1.380 |
Why?
|
| United States | 21 | 2023 | 3894 | 1.210 |
Why?
|
| Antineoplastic Agents | 3 | 2020 | 756 | 1.200 |
Why?
|
| Female | 30 | 2023 | 19873 | 1.130 |
Why?
|
| Hospitalization | 4 | 2023 | 370 | 1.130 |
Why?
|
| Delivery of Health Care | 7 | 2021 | 254 | 0.990 |
Why?
|
| Mastectomy, Segmental | 3 | 2022 | 18 | 0.980 |
Why?
|
| Quality-Adjusted Life Years | 11 | 2022 | 51 | 0.950 |
Why?
|
| Coronary Artery Disease | 1 | 2023 | 147 | 0.850 |
Why?
|
| Critical Illness | 1 | 2022 | 37 | 0.850 |
Why?
|
| Hepatic Encephalopathy | 1 | 2021 | 9 | 0.820 |
Why?
|
| Hematologic Neoplasms | 1 | 2021 | 15 | 0.800 |
Why?
|
| Acute Coronary Syndrome | 2 | 2020 | 35 | 0.800 |
Why?
|
| Aged | 15 | 2023 | 6448 | 0.800 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2020 | 60 | 0.800 |
Why?
|
| Azithromycin | 1 | 2020 | 8 | 0.790 |
Why?
|
| Logistic Models | 4 | 2023 | 894 | 0.780 |
Why?
|
| Risk Factors | 7 | 2023 | 3414 | 0.770 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2020 | 33 | 0.770 |
Why?
|
| Frail Elderly | 1 | 2020 | 15 | 0.760 |
Why?
|
| Antimalarials | 1 | 2020 | 48 | 0.760 |
Why?
|
| Attitude to Death | 1 | 2020 | 20 | 0.750 |
Why?
|
| Life Expectancy | 1 | 2020 | 41 | 0.750 |
Why?
|
| Immunotherapy | 1 | 2021 | 91 | 0.740 |
Why?
|
| Length of Stay | 4 | 2023 | 184 | 0.740 |
Why?
|
| Markov Chains | 6 | 2020 | 32 | 0.740 |
Why?
|
| Databases, Factual | 4 | 2023 | 288 | 0.740 |
Why?
|
| Papillomavirus Vaccines | 1 | 2022 | 136 | 0.730 |
Why?
|
| Stroke | 2 | 2020 | 274 | 0.730 |
Why?
|
| Pyridines | 1 | 2020 | 113 | 0.720 |
Why?
|
| Sirolimus | 3 | 2014 | 58 | 0.720 |
Why?
|
| Piperazines | 1 | 2020 | 109 | 0.710 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2019 | 31 | 0.710 |
Why?
|
| Continuity of Patient Care | 1 | 2020 | 90 | 0.700 |
Why?
|
| Technology Assessment, Biomedical | 2 | 2019 | 6 | 0.700 |
Why?
|
| Hypoglycemic Agents | 2 | 2018 | 152 | 0.690 |
Why?
|
| Quality of Life | 3 | 2019 | 459 | 0.690 |
Why?
|
| Treatment Outcome | 7 | 2020 | 1349 | 0.670 |
Why?
|
| Anti-Bacterial Agents | 2 | 2023 | 355 | 0.660 |
Why?
|
| Longevity | 1 | 2020 | 143 | 0.660 |
Why?
|
| Incretins | 1 | 2018 | 1 | 0.650 |
Why?
|
| Opioid-Related Disorders | 1 | 2020 | 112 | 0.650 |
Why?
|
| Brain Ischemia | 1 | 2020 | 179 | 0.650 |
Why?
|
| Medication Therapy Management | 1 | 2018 | 12 | 0.640 |
Why?
|
| Papillomavirus Infections | 1 | 2022 | 316 | 0.630 |
Why?
|
| Androstadienes | 2 | 2014 | 18 | 0.630 |
Why?
|
| Adult | 14 | 2023 | 11034 | 0.630 |
Why?
|
| Community Pharmacy Services | 1 | 2018 | 24 | 0.620 |
Why?
|
| Genetic Testing | 1 | 2018 | 71 | 0.620 |
Why?
|
| Attitude to Health | 1 | 2020 | 311 | 0.620 |
Why?
|
| Neoplasm Metastasis | 4 | 2020 | 211 | 0.590 |
Why?
|
| Time Factors | 5 | 2021 | 1681 | 0.570 |
Why?
|
| Blood Glucose | 1 | 2018 | 333 | 0.550 |
Why?
|
| Alzheimer Disease | 1 | 2023 | 881 | 0.550 |
Why?
|
| Hormones | 1 | 2015 | 51 | 0.520 |
Why?
|
| Peptides | 1 | 2018 | 308 | 0.520 |
Why?
|
| Thiocarbamates | 1 | 2014 | 4 | 0.510 |
Why?
|
| Child | 5 | 2022 | 2875 | 0.510 |
Why?
|
| Insurance, Health, Reimbursement | 2 | 2011 | 20 | 0.500 |
Why?
|
| Budgets | 1 | 2014 | 10 | 0.500 |
Why?
|
| Reimbursement Mechanisms | 1 | 2013 | 10 | 0.490 |
Why?
|
| Economics, Medical | 1 | 2013 | 3 | 0.480 |
Why?
|
| Middle Aged | 10 | 2022 | 9642 | 0.470 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2018 | 592 | 0.470 |
Why?
|
| Medicare | 7 | 2023 | 188 | 0.460 |
Why?
|
| Neoplasm Staging | 3 | 2020 | 269 | 0.440 |
Why?
|
| Formularies as Topic | 1 | 2011 | 3 | 0.420 |
Why?
|
| Cross-Sectional Studies | 5 | 2023 | 2561 | 0.420 |
Why?
|
| Hepatitis C, Chronic | 2 | 2022 | 39 | 0.420 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2020 | 36 | 0.410 |
Why?
|
| Developing Countries | 1 | 2011 | 97 | 0.400 |
Why?
|
| Cote d'Ivoire | 3 | 2020 | 6 | 0.400 |
Why?
|
| Decision Trees | 3 | 2020 | 18 | 0.400 |
Why?
|
| Health Care Costs | 3 | 2021 | 69 | 0.390 |
Why?
|
| Prescription Drugs | 1 | 2011 | 31 | 0.390 |
Why?
|
| Melanoma | 2 | 2021 | 91 | 0.360 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2021 | 233 | 0.360 |
Why?
|
| Young Adult | 6 | 2021 | 4012 | 0.360 |
Why?
|
| Aged, 80 and over | 4 | 2020 | 2333 | 0.350 |
Why?
|
| Attitude of Health Personnel | 1 | 2011 | 186 | 0.350 |
Why?
|
| Physicians | 1 | 2011 | 148 | 0.340 |
Why?
|
| Drug Therapy, Combination | 2 | 2020 | 217 | 0.340 |
Why?
|
| Male | 10 | 2022 | 18870 | 0.340 |
Why?
|
| Child, Preschool | 3 | 2022 | 1318 | 0.330 |
Why?
|
| Choice Behavior | 2 | 2021 | 75 | 0.330 |
Why?
|
| Norpregnenes | 1 | 2007 | 2 | 0.320 |
Why?
|
| Hot Flashes | 1 | 2007 | 7 | 0.320 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2007 | 18 | 0.320 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2007 | 44 | 0.310 |
Why?
|
| Risk Assessment | 2 | 2020 | 727 | 0.310 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2021 | 375 | 0.300 |
Why?
|
| Adolescent | 4 | 2021 | 5035 | 0.300 |
Why?
|
| Taxoids | 2 | 2017 | 36 | 0.280 |
Why?
|
| Disease Progression | 3 | 2020 | 580 | 0.260 |
Why?
|
| Health Resources | 2 | 2016 | 32 | 0.260 |
Why?
|
| Probability | 2 | 2016 | 75 | 0.260 |
Why?
|
| Hepacivirus | 2 | 2022 | 59 | 0.250 |
Why?
|
| Postmenopause | 2 | 2019 | 125 | 0.250 |
Why?
|
| Substance-Related Disorders | 2 | 2021 | 685 | 0.250 |
Why?
|
| Aortic Aneurysm | 1 | 2023 | 5 | 0.240 |
Why?
|
| Canada | 3 | 2016 | 121 | 0.240 |
Why?
|
| Antiviral Agents | 2 | 2022 | 148 | 0.240 |
Why?
|
| Cardiovascular Diseases | 2 | 2021 | 628 | 0.230 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2022 | 14 | 0.220 |
Why?
|
| Respiratory Tract Infections | 1 | 2022 | 31 | 0.220 |
Why?
|
| Drug Users | 1 | 2022 | 42 | 0.220 |
Why?
|
| Florida | 2 | 2021 | 358 | 0.210 |
Why?
|
| Depressive Disorder, Major | 1 | 2023 | 102 | 0.210 |
Why?
|
| Diabetic Nephropathies | 1 | 2022 | 53 | 0.210 |
Why?
|
| Propensity Score | 2 | 2023 | 40 | 0.210 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2022 | 123 | 0.200 |
Why?
|
| Hepatitis C | 1 | 2022 | 120 | 0.200 |
Why?
|
| Hospital Costs | 1 | 2021 | 22 | 0.200 |
Why?
|
| Refuse Disposal | 1 | 2021 | 16 | 0.200 |
Why?
|
| Patient Preference | 1 | 2021 | 46 | 0.200 |
Why?
|
| Torsades de Pointes | 1 | 2020 | 2 | 0.200 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2020 | 5 | 0.200 |
Why?
|
| Bariatric Surgery | 1 | 2021 | 14 | 0.200 |
Why?
|
| Papillomaviridae | 1 | 2022 | 125 | 0.200 |
Why?
|
| Long QT Syndrome | 1 | 2020 | 12 | 0.200 |
Why?
|
| United States Food and Drug Administration | 1 | 2020 | 22 | 0.200 |
Why?
|
| Prospective Studies | 2 | 2022 | 1353 | 0.200 |
Why?
|
| Radiotherapy | 1 | 2020 | 15 | 0.200 |
Why?
|
| Legislation, Drug | 1 | 2020 | 5 | 0.190 |
Why?
|
| Cohort Studies | 2 | 2023 | 1422 | 0.190 |
Why?
|
| Predictive Value of Tests | 2 | 2020 | 424 | 0.190 |
Why?
|
| Drugs, Generic | 1 | 2020 | 4 | 0.190 |
Why?
|
| Radiosurgery | 1 | 2020 | 61 | 0.190 |
Why?
|
| Vaccination | 1 | 2022 | 259 | 0.190 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2020 | 14 | 0.190 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2021 | 77 | 0.190 |
Why?
|
| Taiwan | 1 | 2019 | 11 | 0.190 |
Why?
|
| Electrocardiography | 1 | 2020 | 154 | 0.180 |
Why?
|
| Survival Rate | 1 | 2020 | 310 | 0.180 |
Why?
|
| Nitriles | 1 | 2019 | 66 | 0.180 |
Why?
|
| Quinolines | 1 | 2020 | 60 | 0.180 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2020 | 82 | 0.180 |
Why?
|
| Brain Neoplasms | 1 | 2020 | 105 | 0.180 |
Why?
|
| Atherosclerosis | 1 | 2021 | 131 | 0.180 |
Why?
|
| Computer Simulation | 2 | 2020 | 347 | 0.180 |
Why?
|
| Anticoagulants | 1 | 2020 | 97 | 0.170 |
Why?
|
| Triazoles | 1 | 2019 | 85 | 0.170 |
Why?
|
| Monte Carlo Method | 2 | 2016 | 55 | 0.170 |
Why?
|
| Atrial Fibrillation | 1 | 2020 | 105 | 0.170 |
Why?
|
| Ticlopidine | 1 | 2018 | 15 | 0.160 |
Why?
|
| Maytansine | 1 | 2017 | 1 | 0.160 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2018 | 26 | 0.160 |
Why?
|
| Survival Analysis | 1 | 2018 | 322 | 0.160 |
Why?
|
| Adenosine | 1 | 2018 | 54 | 0.160 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2016 | 16 | 0.150 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2016 | 12 | 0.150 |
Why?
|
| Hormone Replacement Therapy | 1 | 2016 | 41 | 0.150 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 465 | 0.150 |
Why?
|
| Mexico | 1 | 2017 | 223 | 0.150 |
Why?
|
| Hypoglycemia | 1 | 2016 | 17 | 0.150 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 142 | 0.140 |
Why?
|
| Homosexuality, Male | 1 | 2022 | 438 | 0.140 |
Why?
|
| Lung Neoplasms | 1 | 2020 | 336 | 0.140 |
Why?
|
| Program Evaluation | 1 | 2018 | 316 | 0.140 |
Why?
|
| Prevalence | 1 | 2020 | 1425 | 0.140 |
Why?
|
| Vinblastine | 1 | 2015 | 9 | 0.130 |
Why?
|
| Drug Therapy | 1 | 2015 | 18 | 0.130 |
Why?
|
| Hypnotics and Sedatives | 1 | 2015 | 27 | 0.130 |
Why?
|
| Accidental Falls | 1 | 2015 | 26 | 0.130 |
Why?
|
| Age Factors | 1 | 2018 | 1007 | 0.130 |
Why?
|
| Decision Making, Organizational | 1 | 2014 | 6 | 0.130 |
Why?
|
| Health Records, Personal | 1 | 2014 | 5 | 0.120 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2015 | 58 | 0.120 |
Why?
|
| Medical Oncology | 1 | 2014 | 26 | 0.120 |
Why?
|
| Severity of Illness Index | 2 | 2019 | 608 | 0.120 |
Why?
|
| Receptors, Progesterone | 1 | 2014 | 78 | 0.120 |
Why?
|
| Receptors, Estrogen | 1 | 2014 | 145 | 0.120 |
Why?
|
| Clinical Trials as Topic | 1 | 2014 | 195 | 0.110 |
Why?
|
| Models, Theoretical | 1 | 2013 | 210 | 0.110 |
Why?
|
| Health Priorities | 1 | 2011 | 18 | 0.110 |
Why?
|
| National Health Programs | 1 | 2011 | 18 | 0.100 |
Why?
|
| Feasibility Studies | 1 | 2011 | 196 | 0.100 |
Why?
|
| Algorithms | 1 | 2014 | 435 | 0.100 |
Why?
|
| Health Services Accessibility | 1 | 2013 | 531 | 0.090 |
Why?
|
| Signal Transduction | 1 | 2018 | 1802 | 0.090 |
Why?
|
| Social Class | 1 | 2011 | 228 | 0.090 |
Why?
|
| Estrogens, Conjugated (USP) | 1 | 2007 | 11 | 0.080 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 2007 | 11 | 0.080 |
Why?
|
| Drug Administration Schedule | 1 | 2007 | 145 | 0.080 |
Why?
|
| Incidence | 2 | 2022 | 882 | 0.070 |
Why?
|
| Fluoroquinolones | 1 | 2023 | 6 | 0.060 |
Why?
|
| Macrolides | 1 | 2023 | 11 | 0.060 |
Why?
|
| Antidepressive Agents | 1 | 2023 | 53 | 0.060 |
Why?
|
| Uncertainty | 1 | 2022 | 25 | 0.050 |
Why?
|
| Glucosides | 1 | 2022 | 15 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 133 | 0.050 |
Why?
|
| Benzhydryl Compounds | 1 | 2022 | 42 | 0.050 |
Why?
|
| Insurance Claim Review | 1 | 2021 | 24 | 0.050 |
Why?
|
| Secondary Prevention | 1 | 2021 | 37 | 0.050 |
Why?
|
| Population Surveillance | 1 | 2022 | 231 | 0.050 |
Why?
|
| Australia | 1 | 2020 | 76 | 0.050 |
Why?
|
| Therapeutic Equivalency | 1 | 2020 | 3 | 0.050 |
Why?
|
| Palliative Care | 1 | 2020 | 52 | 0.050 |
Why?
|
| Aspirin | 1 | 2020 | 45 | 0.050 |
Why?
|
| Infant, Newborn | 1 | 2022 | 871 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2020 | 212 | 0.040 |
Why?
|
| Infant | 1 | 2022 | 1014 | 0.040 |
Why?
|
| Needs Assessment | 1 | 2019 | 159 | 0.040 |
Why?
|
| Research Design | 1 | 2019 | 292 | 0.040 |
Why?
|
| Medication Adherence | 1 | 2019 | 165 | 0.040 |
Why?
|
| Hippocampus | 1 | 2020 | 546 | 0.040 |
Why?
|
| Sulfonylurea Compounds | 1 | 2016 | 12 | 0.040 |
Why?
|
| Depression | 1 | 2023 | 664 | 0.040 |
Why?
|
| Models, Biological | 1 | 2020 | 642 | 0.040 |
Why?
|
| Thiazolidinediones | 1 | 2016 | 48 | 0.040 |
Why?
|
| Metformin | 1 | 2016 | 64 | 0.030 |
Why?
|
| Bibliometrics | 1 | 2014 | 16 | 0.030 |
Why?
|
| Insulin | 1 | 2016 | 224 | 0.030 |
Why?
|